PMID- 35733293
OWN - NLM
STAT- MEDLINE
DCOM- 20221220
LR  - 20230201
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 11
IP  - 24
DP  - 2022 Dec
TI  - Concordance of breast cancer biomarker testing in core needle biopsy and surgical 
      specimens: A single institution experience.
PG  - 4954-4965
LID - 10.1002/cam4.4843 [doi]
AB  - BACKGROUND: Accurate diagnostic biomarker testing is crucial to treatment 
      decisions in breast cancer. Biomarker testing is performed on core needle 
      biopsies (CNB) and is often repeated in the surgical specimen (SS) after 
      resection. As differences between CNB and SS testing may alter treatment 
      decisions, we evaluated concordance between CNB and SS as well as associated 
      changes in treatment and clinical outcomes. METHODS: We performed a retrospective 
      analysis of breast cancer patients at our institution between January 2010 and 
      May 2020. Concordance between CNB and SS was assessed for estrogen receptor (ER), 
      progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) 
      by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). 
      Survival in patients, including recurrence, metastatic recurrence, and death, 
      were assessed using chi-squared likelihood ratio. RESULTS: In total, 961 patients 
      met eligibility criteria. Concordance, minor discordance, total concordance 
      (concordance plus minor discordance), and major discordance between CNB and SS 
      were reported for ER (87.7%, 9.2%, 90.8%, and 2.9%), PR (58.1%, 29.1%, 87.2%, and 
      12.8%), and HER2 IHC (52.5%, 20.9%, 73.4%, 26.6%), respectively. HER2 FISH 
      concordance and major discordance were 58.5% and 1.2%, respectively. Of major 
      discordance, ER (48.2%, p < 0.001) and HER2 FISH (50.0%) led to more management 
      changes than HER2 IHC (2.4%, p = 0.04) and PR (1.6%, p = 0.10). Patients with ER 
      major discordance had increased risk of death (6.7% concordance vs. 22.2% major 
      discordance, p = 0.004). CONCLUSION: Overall, retesting ER and HER2 was more 
      clinically beneficial than retesting PR. To aid decision-making and minimize 
      healthcare costs, we propose patient-centered guidelines on retesting biomarker 
      profiles.
CI  - (c) 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Slostad, Jessica A
AU  - Slostad JA
AUID- ORCID: 0000-0002-0202-1767
AD  - Division of Hematology-Oncology, Rush University Medical Center, Chicago, 
      Illinois, USA.
FAU - Yun, Nicole K
AU  - Yun NK
AUID- ORCID: 0000-0002-3668-9618
AD  - Department of Internal Medicine, Rush University Medical Center, Chicago, 
      Illinois, USA.
FAU - Schad, Aimee E
AU  - Schad AE
AD  - Division of Hematology and Medical Oncology, St. Louis University, St. Louis, 
      Missouri, USA.
FAU - Warrior, Surbhi
AU  - Warrior S
AD  - Department of Internal Medicine, Rush University Medical Center, Chicago, 
      Illinois, USA.
FAU - Fogg, Louis F
AU  - Fogg LF
AD  - Department of Community, Systems, and Mental Health Nursing; College of Nursing, 
      Rush University Medical Center, Chicago, Illinois, USA.
FAU - Rao, Ruta
AU  - Rao R
AD  - Division of Hematology-Oncology, Rush University Medical Center, Chicago, 
      Illinois, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220622
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - 0 (Receptors, Estrogen)
SB  - IM
MH  - Humans
MH  - Female
MH  - Biopsy, Large-Core Needle
MH  - *Biomarkers, Tumor/metabolism
MH  - *Breast Neoplasms/diagnosis/surgery/drug therapy
MH  - In Situ Hybridization, Fluorescence
MH  - Retrospective Studies
MH  - Receptors, Progesterone/metabolism
MH  - Receptor, ErbB-2/metabolism
MH  - Receptors, Estrogen/metabolism
PMC - PMC9761085
OTO - NOTNLM
OT  - breast cancer
OT  - core needle biopsy
OT  - estrogen receptor
OT  - progesterone receptor
OT  - surgical pathology
OT  - tyrosine kinase-type cell surface receptor (human epidermal growth factor 
      receptor 2 HER2)
EDAT- 2022/06/24 06:00
MHDA- 2022/12/21 06:00
PMCR- 2022/06/22
CRDT- 2022/06/23 00:52
PHST- 2022/04/24 00:00 [revised]
PHST- 2021/12/13 00:00 [received]
PHST- 2022/05/05 00:00 [accepted]
PHST- 2022/06/24 06:00 [pubmed]
PHST- 2022/12/21 06:00 [medline]
PHST- 2022/06/23 00:52 [entrez]
PHST- 2022/06/22 00:00 [pmc-release]
AID - CAM44843 [pii]
AID - 10.1002/cam4.4843 [doi]
PST - ppublish
SO  - Cancer Med. 2022 Dec;11(24):4954-4965. doi: 10.1002/cam4.4843. Epub 2022 Jun 22.